Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Viral | 2 | 2021 | 110 | 0.750 |
Why?
|
| Valproic Acid | 1 | 2021 | 93 | 0.730 |
Why?
|
| Cefoxitin | 1 | 2020 | 20 | 0.720 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2020 | 22 | 0.710 |
Why?
|
| Anticonvulsants | 1 | 2021 | 223 | 0.670 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 58 | 0.620 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 481 | 0.620 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 91 | 0.600 |
Why?
|
| Bacterial Infections | 1 | 2018 | 163 | 0.570 |
Why?
|
| Sepsis | 1 | 2018 | 233 | 0.520 |
Why?
|
| Anti-Bacterial Agents | 4 | 2021 | 1026 | 0.430 |
Why?
|
| Clinical Chemistry Tests | 1 | 2012 | 2 | 0.420 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 17 | 0.420 |
Why?
|
| Hyperkalemia | 1 | 2012 | 21 | 0.410 |
Why?
|
| Potassium | 1 | 2012 | 168 | 0.400 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 100 | 0.400 |
Why?
|
| Artifacts | 1 | 2012 | 125 | 0.390 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2021 | 133 | 0.330 |
Why?
|
| Warfarin | 1 | 2009 | 93 | 0.320 |
Why?
|
| Genotype | 2 | 2010 | 786 | 0.300 |
Why?
|
| Anticoagulants | 1 | 2009 | 356 | 0.280 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2011 | 11 | 0.270 |
Why?
|
| Quality Control | 2 | 2018 | 81 | 0.260 |
Why?
|
| Lipoproteins, HDL | 1 | 2005 | 113 | 0.240 |
Why?
|
| Laboratories | 2 | 2021 | 44 | 0.230 |
Why?
|
| Troponin I | 1 | 2023 | 34 | 0.220 |
Why?
|
| Creatinine | 2 | 2020 | 243 | 0.210 |
Why?
|
| Immunoassay | 2 | 2022 | 64 | 0.210 |
Why?
|
| Clinical Laboratory Services | 2 | 2020 | 3 | 0.210 |
Why?
|
| Triiodothyronine | 1 | 2022 | 22 | 0.200 |
Why?
|
| Thyroid Function Tests | 1 | 2022 | 21 | 0.200 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 396 | 0.200 |
Why?
|
| Humans | 16 | 2023 | 68618 | 0.200 |
Why?
|
| Specimen Handling | 1 | 2021 | 47 | 0.190 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 20 | 0.190 |
Why?
|
| Resource Allocation | 1 | 2020 | 35 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 67 | 0.180 |
Why?
|
| Mixed Function Oxygenases | 2 | 2010 | 35 | 0.180 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 60 | 0.170 |
Why?
|
| Models, Molecular | 1 | 2021 | 546 | 0.170 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 245 | 0.170 |
Why?
|
| Phosphoproteins | 1 | 2020 | 202 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 507 | 0.170 |
Why?
|
| Oligosaccharides | 1 | 2018 | 26 | 0.160 |
Why?
|
| Fucose | 1 | 2018 | 25 | 0.160 |
Why?
|
| Myocardium | 1 | 2005 | 1204 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2018 | 11 | 0.160 |
Why?
|
| Lectins | 1 | 2018 | 81 | 0.160 |
Why?
|
| Immunochemistry | 1 | 2018 | 17 | 0.160 |
Why?
|
| Chemistry, Clinical | 1 | 2018 | 6 | 0.160 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 33 | 0.160 |
Why?
|
| Biofilms | 1 | 2018 | 72 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 109 | 0.150 |
Why?
|
| Biomarkers | 2 | 2023 | 1593 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2020 | 400 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1753 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2016 | 43 | 0.130 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2015 | 24 | 0.130 |
Why?
|
| Gels | 1 | 2015 | 55 | 0.130 |
Why?
|
| Fluorescence | 1 | 2015 | 104 | 0.120 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 272 | 0.120 |
Why?
|
| Pheochromocytoma | 1 | 2014 | 22 | 0.120 |
Why?
|
| Algorithms | 1 | 2020 | 1196 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2014 | 26 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1851 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 2358 | 0.120 |
Why?
|
| Critical Pathways | 1 | 2014 | 33 | 0.120 |
Why?
|
| South Carolina | 1 | 2020 | 2752 | 0.120 |
Why?
|
| Vitamin K Epoxide Reductases | 2 | 2010 | 4 | 0.110 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2010 | 5 | 0.110 |
Why?
|
| Centrifugation | 1 | 2012 | 16 | 0.100 |
Why?
|
| Hemolysis | 1 | 2012 | 39 | 0.100 |
Why?
|
| Phlebotomy | 1 | 2012 | 17 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2012 | 137 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 91 | 0.100 |
Why?
|
| Adolescent | 2 | 2023 | 8912 | 0.100 |
Why?
|
| Proteins | 1 | 2015 | 474 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 4848 | 0.100 |
Why?
|
| Genotyping Techniques | 1 | 2011 | 19 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2010 | 5 | 0.090 |
Why?
|
| Glucuronosyltransferase | 1 | 2010 | 38 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2010 | 144 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 47 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2077 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 627 | 0.090 |
Why?
|
| Young Adult | 1 | 2020 | 5717 | 0.080 |
Why?
|
| Ligands | 2 | 2021 | 317 | 0.080 |
Why?
|
| Cell Line | 3 | 2011 | 1752 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 131 | 0.080 |
Why?
|
| Mass Spectrometry | 2 | 2007 | 284 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 710 | 0.070 |
Why?
|
| Aged | 2 | 2020 | 14862 | 0.070 |
Why?
|
| United States | 3 | 2020 | 7367 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 104 | 0.070 |
Why?
|
| Albuminuria | 1 | 2007 | 171 | 0.070 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 50 | 0.060 |
Why?
|
| Middle Aged | 2 | 2020 | 21147 | 0.060 |
Why?
|
| Reference Standards | 2 | 2020 | 115 | 0.060 |
Why?
|
| Adult | 2 | 2020 | 21403 | 0.060 |
Why?
|
| Time Factors | 1 | 2012 | 4655 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2005 | 954 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 127 | 0.050 |
Why?
|
| Chest Pain | 1 | 2023 | 151 | 0.050 |
Why?
|
| Genome, Bacterial | 1 | 2021 | 20 | 0.050 |
Why?
|
| Virulence | 1 | 2021 | 51 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2021 | 70 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2022 | 67 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2C19 | 2 | 2011 | 4 | 0.050 |
Why?
|
| Bilirubin | 1 | 2020 | 51 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 31 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 63 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 161 | 0.040 |
Why?
|
| Alleles | 2 | 2011 | 386 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2020 | 104 | 0.040 |
Why?
|
| Blood Group Antigens | 1 | 2018 | 4 | 0.040 |
Why?
|
| Carbohydrate Sequence | 1 | 2018 | 45 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 2018 | 33 | 0.040 |
Why?
|
| Glycosylation | 1 | 2018 | 185 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 711 | 0.040 |
Why?
|
| Rats | 1 | 2005 | 5300 | 0.030 |
Why?
|
| Arizona | 1 | 2016 | 9 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 592 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1027 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 772 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 330 | 0.030 |
Why?
|
| Child | 1 | 2023 | 6405 | 0.020 |
Why?
|
| Pathology, Molecular | 1 | 2010 | 5 | 0.020 |
Why?
|
| Genome, Human | 1 | 2010 | 62 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2800 | 0.020 |
Why?
|
| Genomics | 1 | 2011 | 168 | 0.020 |
Why?
|
| Male | 2 | 2023 | 37321 | 0.020 |
Why?
|
| DNA | 1 | 2010 | 597 | 0.020 |
Why?
|
| Animals | 1 | 2005 | 20881 | 0.020 |
Why?
|
| Nitrogen Isotopes | 1 | 2007 | 13 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2007 | 30 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2007 | 120 | 0.020 |
Why?
|
| Female | 1 | 2016 | 38074 | 0.010 |
Why?
|